Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Public ClinicalTrials.gov record NCT04420975. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial studies the side effects of BO-112 when given together with nivolumab before surgery in treating patients with soft tissue sarcoma that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with BO-112, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab and BO-112 before surgery may work better in treating patients with soft tissue sarcoma compared to nivolumab alone.
Study identification
- NCT ID
- NCT04420975
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 14 participants
Conditions and interventions
Conditions
- Leiomyosarcoma
- Malignant Peripheral Nerve Sheath Tumor
- Myxofibrosarcoma
- Pleomorphic Rhabdomyosarcoma
- Resectable Dedifferentiated Liposarcoma
- Resectable Soft Tissue Sarcoma
- Resectable Undifferentiated Pleomorphic Sarcoma
- Soft Tissue Fibrosarcoma
- Spindle Cell Sarcoma
- Stage I Retroperitoneal Sarcoma AJCC (American Joint Committee on Cancer) v8
- Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Stage IA Retroperitoneal Sarcoma AJCC v8
- Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Stage IB Retroperitoneal Sarcoma AJCC v8
- Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Stage II Retroperitoneal Sarcoma AJCC v8
- Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Stage III Retroperitoneal Sarcoma AJCC v8
- Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Stage IIIA Retroperitoneal Sarcoma AJCC v8
- Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Stage IIIB Retroperitoneal Sarcoma AJCC v8
- Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Storiform-Pleomorphic Malignant Fibrous Histiocytoma
- Synovial Sarcoma
- Undifferentiated High Grade Pleomorphic Sarcoma of Bone
- Undifferentiated Pleomorphic Sarcoma
- Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells
- Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant
- Undifferentiated Spindle Cell Sarcoma
Interventions
- Definitive Surgical Resection Procedure
- Nanoplexed Poly I:C BO-112 Biological
- Nivolumab Biological
- Radiation Therapy Radiation
Procedure · Biological · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 14, 2020 (Actual)
- Primary completion
- Jan 31, 2027 (Estimated)
- Completion
- Jan 31, 2028 (Estimated)
- Last update posted
- Mar 10, 2026
2020 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04420975, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04420975 live on ClinicalTrials.gov.